钠-葡萄糖协同转运蛋白 2 抑制剂对骨骼健康的不良影响。
Adverse effects of SGLT2 inhibitors on bone health.
机构信息
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
出版信息
Nat Rev Nephrol. 2018 Aug;14(8):473-474. doi: 10.1038/s41581-018-0028-0.
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors offer attractive metabolic and cardiorenal benefits for patients with type 2 diabetes, but are associated with a number of safety issues. A recent study documented that SGTL2 inhibition indirectly triggers the FGF23/1,25-dihydroxyvitamin D/parathyroid hormone axis, which may contribute to adverse effects on bone health.
摘要
钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂为 2 型糖尿病患者提供了有吸引力的代谢和心肾益处，但与许多安全问题相关。最近的一项研究表明，SGTL2 抑制间接触发了 FGF23/1,25-二羟维生素 D/甲状旁腺激素轴，这可能导致对骨骼健康的不良影响。
相似文献
1
Adverse effects of SGLT2 inhibitors on bone health.钠-葡萄糖协同转运蛋白 2 抑制剂对骨骼健康的不良影响。
Nat Rev Nephrol. 2018 Aug;14(8):473-474. doi: 10.1038/s41581-018-0028-0.
2
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.在一项随机交叉研究中，卡格列净在健康志愿者中触发了 FGF23/1,25-二羟维生素 D/PTH 轴。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.99123.
3
Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?钠-葡萄糖协同转运蛋白2抑制剂与骨折：风险究竟有多大？
Drug Saf. 2017 Feb;40(2):115-119. doi: 10.1007/s40264-016-0470-5.
4
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病患者矿物质代谢和骨骼的影响。
Curr Med Res Opin. 2016 Aug;32(8):1375-85. doi: 10.1080/03007995.2016.1174841. Epub 2016 May 6.
5
Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.不同阶段慢性肾脏病犬维生素D代谢产物与甲状旁腺激素、成纤维细胞生长因子-23、钙和磷的相关性
J Vet Intern Med. 2017 May;31(3):791-798. doi: 10.1111/jvim.14653. Epub 2017 Feb 10.
6
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病患者骨骼的影响
Postgrad Med. 2017 Jan;129(1):159-168. doi: 10.1080/00325481.2017.1256747. Epub 2016 Nov 28.
7
SGLT2 Inhibitors and Euglycemic Ketoacidosis.钠-葡萄糖协同转运蛋白2抑制剂与正常血糖性酮症酸中毒
Am J Ther. 2018 Jul/Aug;25(4):e498-e500. doi: 10.1097/MJT.0000000000000587.
8
Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.CKD 患者的骨折：欧洲钙化组织协会和欧洲肾脏协会肾脏病透析与移植分会成员的综述
Kidney Int. 2017 Dec;92(6):1343-1355. doi: 10.1016/j.kint.2017.07.021. Epub 2017 Sep 28.
9
Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients.肾移植受者的维生素D、甲状旁腺激素及骨矿物质密度状况
Iran J Kidney Dis. 2012 Jul;6(4):295-9.
10
Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.与钠-葡萄糖协同转运蛋白2抑制剂卡格列净相关的范科尼综合征。
Nephrology (Carlton). 2018 May;23(5):493. doi: 10.1111/nep.13094.
引用本文的文献
1
Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽1受体激动剂在老年2型糖尿病患者中的疗效和安全性比较：一项荟萃分析。
Front Endocrinol (Lausanne). 2025 Aug 26;16:1486655. doi: 10.3389/fendo.2025.1486655. eCollection 2025.
2
Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice.在常规临床实践中，日本 2 型糖尿病患者使用托格列净的安全性和有效性：一项多中心前瞻性观察研究。
J Diabetes Investig. 2024 Nov;15(11):1585-1595. doi: 10.1111/jdi.14287. Epub 2024 Aug 14.
3
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.胰高血糖素样肽-1 受体激动剂与糖尿病性骨病：肠促胰岛素的又一积极作用？一项为期 12 个月的纵向研究。
Calcif Tissue Int. 2024 Aug;115(2):160-168. doi: 10.1007/s00223-024-01240-1. Epub 2024 Jun 12.
4
Fractures in women with type 2 diabetes are associated with marked deficits in cortical parameters and trabecular plates.患有 2 型糖尿病的女性骨折与皮质参数和小梁板明显减少有关。
J Bone Miner Res. 2024 Aug 21;39(8):1083-1093. doi: 10.1093/jbmr/zjae091.
5
Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者骨代谢的影响：一项系统评价和荟萃分析
BMC Endocr Disord. 2024 Apr 24;24(1):52. doi: 10.1186/s12902-024-01575-8.
6
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.评价比格列净在中国 2 型糖尿病患者中的疗效和安全性：一项为期 24 周、随机、双盲、阳性对照、3 期临床试验，与达格列净作为二甲双胍的辅助治疗。
J Diabetes. 2024 Apr;16(4):e13526. doi: 10.1111/1753-0407.13526.
7
Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects.通过回顾全身血糖外效应评估钠-葡萄糖协同转运蛋白2抑制剂在糖尿病合并症患者中的药物安全性
Diabetes Metab Syndr Obes. 2024 Mar 6;17:1131-1141. doi: 10.2147/DMSO.S448670. eCollection 2024.
8
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与跌倒和骨折报告：一项欧洲药物警戒分析
Front Pharmacol. 2023 Nov 6;14:1245642. doi: 10.3389/fphar.2023.1245642. eCollection 2023.
9
Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.2型糖尿病合并估算肾小球滤过率降低患者中钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的处方率
Innov Pharm. 2023 Oct 10;14(2). doi: 10.24926/iip.v14i2.5456. eCollection 2023.
10
Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients.钠-葡萄糖协同转运蛋白2抑制剂在肾移植受者中的应用。
World J Transplant. 2023 Sep 18;13(5):239-249. doi: 10.5500/wjt.v13.i5.239.
本文引用的文献
1
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.在一项随机交叉研究中，卡格列净在健康志愿者中触发了 FGF23/1,25-二羟维生素 D/PTH 轴。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.99123.
2
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.SGLT2 抑制的肾脏、代谢和心血管考虑因素。
Nat Rev Nephrol. 2017 Jan;13(1):11-26. doi: 10.1038/nrneph.2016.170. Epub 2016 Dec 12.
3
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.卡格列净对2型糖尿病患者骨折风险的影响。
J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
4
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.使用卡格列净治疗的2型糖尿病患者的骨密度和骨生物标志物评估。
J Clin Endocrinol Metab. 2016 Jan;101(1):44-51. doi: 10.1210/jc.2015-1860. Epub 2015 Nov 18.
5
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.对2型糖尿病合并中度肾功能损害患者的长期研究表明，达格列净可减轻体重和降低血压，但不能改善血糖控制。
Kidney Int. 2014 Apr;85(4):962-71. doi: 10.1038/ki.2013.356. Epub 2013 Sep 25.
Zotero 插件